Valeant Pharmaceuticals International Inc. (VRX)

18.68
NYSE : Health Technology
Prev Close 18.27
Day Low/High 18.21 / 18.84
52 Wk Low/High 8.31 / 24.43
Avg Volume 15.55M
Exchange NYSE
Shares Outstanding 348.59M
Market Cap 6.49B
EPS -6.90
P/E Ratio 4.67
Div & Yield N.A. (N.A)

Latest News

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Insurgent managers had another busy year. But behind the numbers there were some fascinating trends and surprising tactics. Here's our review of the year that was.

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.

Cramer: These CEOs Are Creating Value

Cramer: These CEOs Are Creating Value

Not all stocks are created equal and it's the CEOs who make the difference.

Jim Cramer: Why the Stock Market Isn't Falling

Jim Cramer: Why the Stock Market Isn't Falling

There are plenty of reasons why the stock market isn't falling, from defense and aerospace, to booming energy, to reduced regulation.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Valeant Stock Tumbles on $750 Million Debt Offering Announcement

Valeant Stock Tumbles on $750 Million Debt Offering Announcement

The notes are due in 2025. Proceeds from the offering will help pay down some of Valeant's more than $26 billion debt load.

Is Valeant Pharmaceuticals Coming Back From the Dead?

Is Valeant Pharmaceuticals Coming Back From the Dead?

The stock is performing better than it has in a long time.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:

Valeant's Explosive Gains Make the Stock Look Buyable Again

Valeant's Explosive Gains Make the Stock Look Buyable Again

Valeant has long been a stock that nobody wanted to touch -- but drama-free earnings and a bullish breakout move are actually making this stock look buyable in the final stretch of 2017.

Ackman Vows to Return to ADP; Valeant Rises After Asset Sale -- ICYMI

Ackman Vows to Return to ADP; Valeant Rises After Asset Sale -- ICYMI

Here's what you need to know now for Tuesday, Nov. 7.

Bill Ackman Overwhelmingly Loses ADP Battle in Latest Blow to Activist Investor

Bill Ackman Overwhelmingly Loses ADP Battle in Latest Blow to Activist Investor

The insurgent hedge fund manager, who suggested he may be back in 2018 with another boardroom battle, fails in his effort to elect three dissident directors to the board of the payroll processor.

General Electric, Toyota, Snap - 5 Things You Must Know Before the Market Opens

General Electric, Toyota, Snap - 5 Things You Must Know Before the Market Opens

U.S. stock futures suggest Wall Street will open mixed on Tuesday, after the benchmark indexes rallied to fresh records during the previous trading session.

Valeant Divests Subsidiary Developing Female Libido Treatment

Valeant Divests Subsidiary Developing Female Libido Treatment

Valeant will divest its subsidiary Sprout Pharmaceuticals to former Sprout shareholders after Sprout accused Valeant of mishandling the launch and marketing of one of its drugs.

Futures Up After Lukewarm Jobs Report Friday

Futures Up After Lukewarm Jobs Report Friday

Wages and job numbers rose less than expected, but September payrolls were advised to reverse a loss.

Surprise Arrest of Saudi Billionaire Alwaleed Bin Talal Overshadows Big Earnings

Surprise Arrest of Saudi Billionaire Alwaleed Bin Talal Overshadows Big Earnings

Walt Disney, the largest entertainment company in the world, will open its books for investors on Thursday. But until then, all eyes on the surprising arrest of Saudi Prince Alwaleed Bin Talal.

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Will the benign backdrop continue next week? Cramer has a defensive game plan, in case earnings chill the market.

Apple Rally Drives Dow, S&P 500 and Nasdaq to New Records

Apple Rally Drives Dow, S&P 500 and Nasdaq to New Records

Apple carries the Dow Jones Industrial Average and broader markets to records to close out the week.

Dow on Track for Record If Gains Hold as Apple Rallies on Earnings

Dow on Track for Record If Gains Hold as Apple Rallies on Earnings

Apple could carry the Dow Jones Industrial Average to new records but only if the blue-chip index can hold onto small gains through the afternoon session.

Valeant Pharmaceuticals Stock Jumps on FDA Approval of This Glaucoma Treatment

Valeant Pharmaceuticals Stock Jumps on FDA Approval of This Glaucoma Treatment

Valeant subsidiary Bausch + Lomb, along with Nicox S.A., received FDA application approval for a new glaucoma drug.

Stocks Mixed as Wall Street Weighs Job Growth With Wage Weakness

Stocks Mixed as Wall Street Weighs Job Growth With Wage Weakness

Stocks hold mixed on Friday, Nov. 3, as markets digest a strong rebound in jobs growth but weaker wages.

Stock Futures Hold Higher After U.S. Adds 261,000 in October

Stock Futures Hold Higher After U.S. Adds 261,000 in October

Stock futures hold higher on Friday, Nov. 3, as job growth rebounds in October after hurricanes wreaked havoc with the September number.

Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

First Prostaglandin Analog with one of its Metabolites Being Nitric Oxide Approved to Provide Consistent and Sustained IOP Reduction Through 12 Months

Ackman Gets Boost In ADP Battle

Ackman Gets Boost In ADP Battle

Influential shareholder advisory firm supports all of the activist investor's director candidates in a proxy war set to conclude on Nov. 7.

TheStreet Quant Rating: C (Hold)